Atherosclerosis is a common condition in which plaque built up on the arterial wall results in narrowing and hardening of the blood vessel, leading to serious problems like heart attacks, stroke and peripheral vascular diseases. Plaque formation occurs due to accumulation of cholesterol, calcium, lipoprotein and leukocyte on arterial walls. Occlusion of the blood vessel following plaque rupture results in myocardial ischemia and infarction, which can be fatal. Stent implantation after balloon angioplasty is used to mechanically restore vessel dimensions to ensure a proper blood flow. Stent is a small expandable mesh like structure made of stainless steel, platinum–iridium alloy, tantalum, nitinol, cobalt– chromium alloy, titanium, pure iron or magnesium alloys. In 25–50% of the patients, stent implantation stimulates platelet activation, adhesion, thrombosis and fibromuscular proliferation, producing in-stent restenosis, which means re-narrowing of the previously treated blood vessel. Damage to the vessel wall caused by angioplasty procedure and foreign body reactions to the metallic stent seem to trigger immune responses that lead to restenosis. As pathogenesis of restenosis has been identified to have numerous contributing factors, the regulation of one or two factors is insufficient to control the cascade of the restenosis events. Although numerous treatment options are available for controlling restenosis, a site-specific delivery of immunosuppressant drugs is widely accepted to provide a higher benefit/risk ratio than systemic therapies. Additionally, cardiovascular stents were surface coated with various biodegradable and biocompatible polymers containing immunosuppressant drugs to prevent their escalating incidence of restenosis stemmed from in-stent neointimal hyperplasia. Majority of cardiovascular drugs are engaged with Nitric Oxide involved pathways. Since NO is a multifunctional molecule that shows its activity in regulating blood flow, blood pressure and thrombus formation, a continuous and spatiotemporal delivery of NO from the surface coated stent at the implanted site could be a viable option to reduce and prevent restenosis. The development of sustained NO eluting stents poses as a major challenge due to its short physiological half-life. Although numerous studies have been performed to obtain desired therapeutic effects, an optimized releasing polymeric platform is yet to be discovered. S-Nitrosoglutathione is a platelet selective donor. In patients with severe vascular injury like coronary angioplasty, GSNO treatment has been effective in preventing platelet adhesion and aggregation through NO release mediated by platelet membranes-associated enzymes. Due to its selective platelet inhibition action as compared to a vasodilatory action, GSNO could be a potential antithrombotic NO donor for the treatment of restenosis. Design of drug eluting stent for a given drug is an attractive, yet tedious process, due to the difficulty in the screening assessment on clinical NVP-BKM120 efficacy of numerous polymeric carrier systems. It is crucial to broaden the horizon on advanced therapeutic research tools to identify suitable delivery systems against restenosis. Statistical design of experiments reduces conventional optimization tasks and helps navigate through critical challenges in the formulation development process.. This technique is widely utilized in industrial setting, as each step offers statistically sound information and provides cost effective solutions. Statistical DOE offers a formidable opportunity to develop new polymeric carriers for NO delivery. Thus, fractional factorial designs are used as a screening tool at the initial stages of biomedical experiments to identify the essential factors.